ASCO GUIDELINES Bundle

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475468

Contents of this Issue

Navigation

Page 70 of 71

71 12. Prevention and Management of Adverse Events Related to Steroid Use 12.4 Tapering of steroids • The length of steroid-taper should occur according to the type and severity of irAE, the initial steroid dose, and individual patient responses rather than other prespecified criteria. • Steroid taper should occur slowly, generally over 4–6 weeks. • Regular clinical evaluation should occur during steroid tapering as there is a risk of irAE rebound/recurrence. • In general, oral steroid tapering is recommended to occur over 4–6 weeks, with a reduction in prednisone or prednisolone of 10 mg every 3–7 days (as irAE allows) until the dose is 10 mg/day, then reduce by 5 mg every 3–7 days for patients who respond quickly to steroids. For those who have received steroids for several weeks, tapering may be more prolonged. • In general, for patients that require IV steroids, tapering is recommended to occur over 4 weeks or longer. The initial IV conversion from methylprednisolone if ≥1 mg/kg/day would be to oral prednisone 1 mg/kg/day at minimum and then taper as above. • Longer steroid tapers (>4–6 weeks) may be required for complete resolution or to avoid recurrence/rebound of irAE events. • Patients should be monitored for the symptoms of adrenal insufficiency after prolonged exogenous steroids • Stress doses may be needed in the event of illness, injury, surgery • Option when ready to drop below 5 mg of prednisone or 0.5 mg of dexamethasone after a longer course with concern for iatrogenic adrenal insufficiency, is to transition to hydrocortisone at physiologic dosing (10 mg in the morning, 5 mg in the afternoon). This allows for faster recovery of the HPA axis because it restores diurnal patterns. • If indicated to control disease, a simultaneous slow, low dose taper of the long-acting steroid can be given (for example decreasing by 1 mg prednisone per week). • HPA axis function can be tested 24 hours from last oral hydrocortisone (skip PM dose, hold AM dose for labs) — measured AM cortisol and ACTH will reflect endogenous function. Ambiguous results can be clarified with an ACTH stimulation test similarly prepared for. (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy